B J Edwards1, W J Gradishar2,3, M E Smith4, J A Pacheco4, J Holbrook5, J M McKoy2,3,6, B Nardone5, S Tica3, V Godinez-Puig5, A W Rademaker6, I B Helenowski6, A D Bunta7, P H Stern8, S T Rosen2,3, D P West2,5, T A Guise9. 1. Department of General Internal Medicine, University of Texas, MD Anderson Cancer Center, 1515 Holcombe, unit 1465, Houston, TX, 77030, USA. bedwards@mdanderson.org. 2. Robert H. Lurie Comprehensive Cancer Center, Chicago, IL, USA. 3. Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. 4. NUgene Project, Center for Genetic Medicine, Northwestern University, Chicago, IL, USA. 5. Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. 6. Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. 7. Department of Orthopaedic Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. 8. Department of Molecular Pharmacology and Biological Chemistry, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. 9. Department of Medicine, Division of Endocrinology, Indiana University, Indianapolis, IN, USA.
Abstract
UNLABELLED: This study evaluates the incidence of bone fractures in women with BC.We found that women with invasive breast cancer are at an increased risk for bone fractures, with fractures most commonly occurring at lower extremity and vertebral sites. The risk is further increased in women undergoing cancer therapy. INTRODUCTION: Bone loss and fractures in breast cancer have generally been attributed to aromatase inhibitor use. This study assessed the incidence of fractures after invasive breast cancer diagnosis and evaluated bone density and FRAX risk calculation at time of fracture occurrence. METHODS: Retrospective cohort study of women with invasive breast cancer [June 2003-December 2011] who participated in an academic hospital based genetic biobank. Demographic and clinical characteristics were abstracted from the electronic medical record (EMR). RESULTS: A total of 422 women with invasive breast cancer were assessed; 79 (28 %) sustained fractures during the observation period; fractures occurred at multiple skeletal sites in 27 cases (116 fractures). The incidence of fractures was 40 per 1000 person-years. Women who sustained fractures were mostly white and had a family history of osteoporosis (36.9 %, p = 0.03) or history of a prior fracture (6/79, p = 0.004). Fractures occurred 4.0 years (range 0-12 years) after cancer diagnosis. Fracture cases had femoral neck bone mineral density (BMD) of 0.72 + 0.12 g/cm(2), T-score of -1.2, that is, within the low bone mass range. Fractures most commonly occurred in lower extremities, vertebral, and wrist sites. Hip fractures accounted for 11 % of fractures, occurring at a median age of 61 years. CONCLUSIONS: Fractures occur shortly after commencing cancer therapy. Rapid bone loss associated with cancer therapy may precipitate fractures. Fractures occur at relatively higher BMD in BC. Occurrence of fractures in invasive breast cancer raises the possibility of cancer-induced impairment in bone quality.
UNLABELLED: This study evaluates the incidence of bone fractures in women with BC.We found that women with invasive breast cancer are at an increased risk for bone fractures, with fractures most commonly occurring at lower extremity and vertebral sites. The risk is further increased in women undergoing cancer therapy. INTRODUCTION:Bone loss and fractures in breast cancer have generally been attributed to aromatase inhibitor use. This study assessed the incidence of fractures after invasive breast cancer diagnosis and evaluated bone density and FRAX risk calculation at time of fracture occurrence. METHODS: Retrospective cohort study of women with invasive breast cancer [June 2003-December 2011] who participated in an academic hospital based genetic biobank. Demographic and clinical characteristics were abstracted from the electronic medical record (EMR). RESULTS: A total of 422 women with invasive breast cancer were assessed; 79 (28 %) sustained fractures during the observation period; fractures occurred at multiple skeletal sites in 27 cases (116 fractures). The incidence of fractures was 40 per 1000 person-years. Women who sustained fractures were mostly white and had a family history of osteoporosis (36.9 %, p = 0.03) or history of a prior fracture (6/79, p = 0.004). Fractures occurred 4.0 years (range 0-12 years) after cancer diagnosis. Fracture cases had femoral neck bone mineral density (BMD) of 0.72 + 0.12 g/cm(2), T-score of -1.2, that is, within the low bone mass range. Fractures most commonly occurred in lower extremities, vertebral, and wrist sites. Hip fractures accounted for 11 % of fractures, occurring at a median age of 61 years. CONCLUSIONS:Fractures occur shortly after commencing cancer therapy. Rapid bone loss associated with cancer therapy may precipitate fractures. Fractures occur at relatively higher BMD in BC. Occurrence of fractures in invasive breast cancer raises the possibility of cancer-induced impairment in bone quality.
Entities:
Keywords:
Breast cancer; Disability; Fractures; Functional status; Morbidity; Women’s health
Authors: Karen E Lasser; Paul D Allen; Steffie J Woolhandler; David U Himmelstein; Sidney M Wolfe; David H Bor Journal: JAMA Date: 2002-05-01 Impact factor: 56.272
Authors: Beatrice J Edwards; Dennis W Raisch; Veena Shankaran; June M McKoy; William Gradishar; Andrew D Bunta; Athena T Samaras; Simone N Boyle; Charles L Bennett; Dennis P West; Theresa A Guise Journal: Clin Cancer Res Date: 2011-02-01 Impact factor: 12.531
Authors: Stacey A Wainwright; Lynn M Marshall; Kristine E Ensrud; Jane A Cauley; Dennis M Black; Teresa A Hillier; Marc C Hochberg; Molly T Vogt; Eric S Orwoll Journal: J Clin Endocrinol Metab Date: 2005-02-22 Impact factor: 5.958
Authors: Ahmedin Jemal; Ram C Tiwari; Taylor Murray; Asma Ghafoor; Alicia Samuels; Elizabeth Ward; Eric J Feuer; Michael J Thun Journal: CA Cancer J Clin Date: 2004 Jan-Feb Impact factor: 508.702
Authors: Peyman Hadji; Matti S Aapro; Jean-Jacques Body; Michael Gnant; Maria Luisa Brandi; Jean Yves Reginster; M Carola Zillikens; Claus-C Glüer; Tobie de Villiers; Rod Baber; G David Roodman; Cyrus Cooper; Bente Langdahl; Santiago Palacios; John Kanis; Nasser Al-Daghri; Xavier Nogues; Erik Fink Eriksen; Andreas Kurth; Rene Rizzoli; Robert E Coleman Journal: J Bone Oncol Date: 2017-03-23 Impact factor: 4.072
Authors: Rebecca Pedersini; Vito Amoroso; Filippo Maffezzoni; Fabio Gallo; Antonella Turla; Sara Monteverdi; Mara Ardine; Marco Ravanelli; Lucia Vassalli; Filippo Rodella; Anna Maria Formenti; Alberto Dalla Volta; Edda Lucia Simoncini; Andrea Giustina; Roberto Maroldi; Alfredo Berruti Journal: JAMA Netw Open Date: 2019-09-04